Dinner Shira, Lee Daniel, Liedtke Michaela
Division of Hematology, Department of Medicine.
Leuk Lymphoma. 2014 Aug;55(8):1715-24. doi: 10.3109/10428194.2013.856428. Epub 2014 Apr 25.
Despite high rates of complete remission in newly diagnosed adult acute lymphoblastic leukemia (ALL), rates of long-term leukemia-free survival are disappointingly low. Treatment of relapsed disease with chemotherapy, even in patients able to pursue consolidation with allogeneic stem cell transplant, has demonstrated limited success. There are no established standards of care in this setting and few standard treatment options. Novel agents targeting antigens on the lymphoblast cell surface offer unique side effect and anti-leukemic profiles which suggest that their use alone or in combination with chemotherapy may achieve improved outcomes for relapsed or refractory ALL.
尽管新诊断的成人急性淋巴细胞白血病（ALL）完全缓解率很高，但长期无白血病生存率却低得令人失望。即使对于能够接受异基因干细胞移植巩固治疗的患者，用化疗治疗复发性疾病的成功率也有限。在这种情况下没有既定的护理标准，标准治疗选择也很少。靶向淋巴母细胞表面抗原的新型药物具有独特的副作用和抗白血病特性，这表明单独使用或与化疗联合使用可能会改善复发性或难治性ALL的治疗效果。
